SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Precision BioSciences DSMB Clears Additional PBGENE-DMD Dosing

The independent DSMB found no safety concerns after reviewing the first treated patient in the Phase 1/2 study.

DTIL

Related stories